Bradley Merrill Thompson Quoted in “New Clinical Decision Support Software Guidelines Highlight Keys to Self-Regulation”

FierceHealthcare

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in FierceHealthcare, in “New Clinical Decision Support Software Guidelines Highlight Keys to Self-Regulation,” by Evan Sweeney.

Following is an excerpt:

Allowing software to take on a broader role in clinical assessments is “risky,” writes Bradley Merrill Thompson, a medical device attorney with Epstein Becker Green and the Coalition’s general counsel wrote in a LinkedIn post. Therefore, the guidelines focus on four key factors to ensuring software remains as a support tool for independent clinical diagnoses…

“The coalition’s goal is to develop a framework that will provide consistency in user empowerment across software developers,” Thompson wrote. “The key for this unregulated portion of CDS is ensuring that the healthcare professionals can gather and analyze the information needed to make the best recommendations to their patients.”